Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...
The U.S. Food and Drug Administration (FDA) has cleared Crescent’s IND for CR-001, and Crescent’s partner Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”) has received IND approval ...
2d
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an ...
Superb internalization profile paired with proprietary linker technology underscore strong efficacy and optimal stability data; first-in-class ADC program currently in IND-enabling studies CAMBRIDGE, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 ...
Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...
This article is based on a poster originally authored by An Ouyang, Spencer Chiang and Chao Wang. Antibody-drug conjugates (ADCs) are a new class of anti-cancer therapeutics that are both novel and ...
Peptide-drug conjugates (PDCs) are emerging as a promising alternative to antibody-drug conjugates (ADCs), offering enhanced tumor penetration and reduced immunogenicity. Carbonic anhydrase IX (CAIX) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback